115619-01-7

Basic information

• Product Name: 4-(4-Ethylpiperazin-1-ly)aniline
• Synonyms: 4-(4-ethylpiperazin-1-yl)anilinehydrochloride;TIMTEC-BB SBB007132;ART-CHEM-BB B021943;4-(4-ETHYLPIPERAZINO)ANILINE;4-(4-ETHYLPIPERAZIN-1-YL)ANILINE;4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINE;AKOS BB-8659;AKOS B021943
• CAS NO: 115619-01-7
• Molecular Formula: C₁₂H₁₉N₃
• Molecular Weight: 205.3
• Mol File: 115619-01-7.mol
• Article Data: 19

Chemical Properties

• Melting Point: 76-78°C
• Boiling Point: 364.4 °C at 760 mmHg
• Flash Point: 171.6 °C
• Appearance: /
• Density: 1.065 g/cm³
• Vapor Pressure: 1.69E-05mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.05±0.10(Predicted)
• CAS DataBase Reference: 4-(4-Ethylpiperazin-1-ly)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Ethylpiperazin-1-ly)aniline(115619-01-7)
• EPA Substance Registry System: 4-(4-Ethylpiperazin-1-ly)aniline(115619-01-7)

Safety Data

• Hazard Codes: Xi
• RIDADR: 3259
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 115619-01-7(Hazardous Substances Data)

Usage

General Description

4-(4-Ethylpiperazin-1-yl)aniline, also known as EPPA, is a chemical compound that is used primarily as an intermediate in the manufacturing of pharmaceuticals. It is a derivative of piperazine and aniline, and it contains an ethyl group attached to the piperazine ring. EPPA is widely utilized in the synthesis of various drugs, including antipsychotic and antihistamine medications. It is also employed as a research chemical in the development of new pharmaceutical compounds. However, EPPA is considered to be a potentially hazardous substance and should be handled and used with caution due to its potential health and environmental impacts.

InChI:InChI=1/C12H19N3/c1-2-14-7-9-15(10-8-14)12-5-3-11(13)4-6-12/h3-6H,2,7-10,13H2,1H3

Upstream product

• 115619-00-6 1-ethyl-4-(4-nitro-phenyl)-piperazine 
• 5308-25-8 4-ethylpiperazine 
• 636-98-6 p-nitrobenzene iodide 
• 586-78-7 para-nitrophenyl bromide 
• 100-00-5 4-chlorobenzonitrile 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 611225-88-8 4-(4-ethylpiperazinyl)benzeneisothiocyanate 
• 872513-04-7 N²-(4-(4-ethylpiperazin-1-yl)phenyl)-N⁴-methyl-1,3,5-triazine-2,4-diamine 
• 872511-66-5 N-[4-(4-ethyl-piperazin-1-yl)-phenyl]-pyrimidine-4,6-diamine 
• 934496-35-2 6-bromo-8-ethyl-2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one 
• 934496-55-6 6-bromo-2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-4-methyl-8-(1-methylethyl)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 872511-35-8 of N⁴-(4-(4-ethylpiperazin-1-yl)phenyl)-N⁶-methylpyrimidine-4,6-diamine 
• 1030626-94-8 5-chloro-N-(4-(4-ethylpiperazin-1-yl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-8-amine 
• 1197331-55-7 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [4-(4-ethyl-piperazin-1-yl)-phenyl]-amide 
• 1197329-93-3 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1-yl)-phenyl]-amide 
• 1197165-02-8 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-ethylpiperazin-1-yl)phenyl)urea 
• 1197164-96-7 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-ethylpiperazin-1-yl)phenyl)urea 
• 1160061-38-0 C₂₇H₂₆N₈O₂S 
• 1170678-28-0 1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)-phenylamino]-5-iodo-1,3-dihydroindol-2-one 
• 1313481-14-9 6-chloro-N-(4-(4-ethylpiperazin-1-yl)phenyl)-2-methoxyacridin-9-amine 

Relevant articles and documents

FGFR Inhibitor compounds and uses thereof

The invention relates to FGFR inhibitor compounds and uses thereof. , The application discloses a compound as shown in a formula (I). A compound, or an optical isomer, a geometric isomer, a tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof. The application further relates to the application of the compound in medicine.

Discovery and SARs of 5-Chloro- N4-phenyl- N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy. Herein, we describe our efforts toward the discovery of a series of 5-chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as dual CDK6 and 9 inhibitors. Intensive structural modifications lead to the identification of compound 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2. Further biological studies revealed that compound 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis. More importantly, compound 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment. Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.

FUSED PYRIMIDINOPIPERIDINE DERIVATIVE, AND MANUFACTURING METHOD AND APPLICATION THEREOF

The present invention relates to the fused pyrimidine piperidine cyclic derivative represented by the following formula (I) and a pharmaceutically acceptable salt thereof and a process for preparing the same, wherein R1, R2, R3